multi-target hybrid drugs: a promising approach for treating alzheimer's, neurological diseases, diabetes, and cancer

Multi-target drugs are a class of hybrid compounds that can act on multiple targets and diseases simultaneously. these drugs have the potential to treat a range of disorders including alzheimer's disease, diabetes, and cancer. this review aims to assess the efficacy of acridine- and tacrine-based multi-target hybrid drugs for the treatment of various diseases. in december 2022, a systematic literature search was conducted using acridine, tacrine, multi-target agent, and multi-factorial diseases along with their synonyms. according to the findings, acridine-based conjugates exhibited anti-cancer and anti-diabetic properties by directly inhibiting α-glucosidase and α-amylase, and by binding to dna, topoisomerases, histone deacetylase, and poly (adp-ribose) polymerase. the results suggest that acridine- and tacrine-based hybrid complexes have the potential to serve as promising multi-target agents for the treatment of alzheimer's disease, neurological disorders, diabetes, and cancer. overall, these compounds offer a new approach to drug development by targeting multiple disease pathways with a single agent. in conclusion, the use of multi-target drugs could potentially lead to improved therapeutic outcomes with fewer side effects, making them a promising area of research for the treatment of complex diseases. keywords for this review include acridine, tacrine, multi-factorial diseases, and multi-target drugs.